NCT04709380 2025-02-26
Phase III RCT of Radiotherapy Plus Toripalimab Versus Sorafenib in Advanced Hepatocellular Carcinoma With PVTT
Cancer Institute and Hospital, Chinese Academy of Medical Sciences
Phase 3 Terminated
Clinical Trials
89 trialsNCT03878524 2024-03-04
Serial Measurements of Molecular and Architectural Responses to Therapy (SMMART) PRIME Trial
OHSU Knight Cancer Institute
Phase 1 Terminated
NCT00496756 2023-10-26
Sorafenib in Treating Patients With Metastatic or Unresectable Kidney Cancer
University of Nebraska
Phase 2 Terminated
NCT03236649 2023-02-08
The Phase III Study of Icaritin Versus Sorafenib in PD-L1 Positive Advanced Hepatocellular Carcinoma Subjects
Beijing Shenogen Biomedical Co., Ltd
Phase 3 Terminated
NCT03582618 2023-01-10
CVM-1118 and Sorafenib Combination in Subjects With Advanced Hepatocellular Carcinoma
TaiRx, Inc.
Phase 2 Terminated
NCT02575339 2022-07-26
MLN0128 Compared to Sorafenib in Advanced or Metastatic Hepatocellular Carcinoma
Big Ten Cancer Research Consortium
Phase 1/2 Terminated
NCT04326439 2022-06-15
AflacLL1901 (CHOA-AML)
Emory University
Phase 2 Terminated
NCT01620216 2021-11-04
Targeted Therapy in Treating Patients With Relapsed or Refractory Acute Lymphoblastic Leukemia or Acute Myelogenous Leukemia
OHSU Knight Cancer Institute
Phase 2 Terminated
NCT01141478 2021-10-15
HCC
Loma Linda University
Phase NA Terminated
NCT03630120 2021-07-14
Adaptive Tyrosine Kinase Inhibitor (TKI) Therapy In Patients With Thyroid Cancer
H. Lee Moffitt Cancer Center and Research Institute
Phase 2 Terminated
NCT01032850 2021-06-02
Sorafenib With Capecitabine for Patients With Measurable Hepatocellular Carcinoma
New Mexico Cancer Research Alliance
Phase 2 Terminated
NCT01887717 2021-04-21
YES-P
Boston Scientific Corporation
Phase 3 Terminated
NCT02460991 2021-02-12
SOLACE
Boston Scientific Corporation
Phase 3 Terminated
NCT00823290 2020-12-14
Sorafenib and LBH589 in Hepatocellular Carcinoma (HCC)
University of Erlangen-Nürnberg Medical School
Phase 1 Terminated
NCT01190241 2020-11-20
TSAP
Amsterdam UMC, location VUmc
Phase NA Terminated
NCT00622466 2020-10-19
Sorafenib and Paclitaxel in Treating Patients With Metastatic Breast Cancer
University of Texas Southwestern Medical Center
Phase 2 Terminated
NCT00880542 2020-08-10
Sorafenib and Ifosfamide in Treating Patients With High-Grade Soft Tissue Sarcoma or Bone Sarcoma That Can Be Removed by Surgery
Jonsson Comprehensive Cancer Center
Phase 2 Terminated
NCT02624700 2020-07-14
2nd Line Treatment With Pemetrexed and Sorafenib for Recurrent or Metastatic Triple Negative Breast Cancer
Virginia Commonwealth University
Phase 2 Terminated
NCT02867280 2020-02-11
Sorafenib Treatment in Patients With Hepatocellular Carcinoma With Microvascular Invasion After Radical Resection
Sun Yat-sen University
Phase 3 Terminated
NCT00287495 2019-12-12
BAY 43-9006 (Sorafenib) to Treat Patients With Kaposi's Sarcoma
National Institutes of Health Clinical Center (CC)
Phase 1 Terminated
NCT00687674 2019-08-20
Sorafenib, Lenalidomide, and Dexamethasone in Treating Patients With Relapsed or Refractory Multiple Myeloma
Mayo Clinic
Phase 1 Terminated
NCT00727532 2019-05-03
Sorafenib in Treating Patients With Locally Advanced or Metastatic Kidney Cancer
Northwestern University
Phase NA Terminated
NCT00754923 2019-03-06
Sorafenib in Treating Non-Smokers or Former Light Smokers With Relapsed or Refractory Stage IIIB or Stage IV Non-Small Cell Lung Cancer
Ohio State University Comprehensive Cancer Center
Phase 2 Terminated
NCT02748304 2019-02-15
Sorafenib Combined With Aspirin to Prevent the Recurrence in High-risk Patients With Hepatocellular Carcinoma
Fudan University
Phase NA Terminated
NCT02412475 2019-01-24
Epigenetic Reprogramming in Relapse AML
Medical College of Wisconsin
Phase 1 Terminated
NCT02220088 2019-01-11
The Efficacy and Safety of Retreatment With TAI for Patients Who Showed TACE-resistant: a Randomized Controlled Trial
Sun Yat-sen University
Phase 2/3 Terminated
NCT00924807 2018-12-11
Safety Study of Sorafenib With Androgen Deprivation and Radiotherapy to Treat Prostate Cancer
Beth Israel Medical Center
Phase 1/2 Terminated
NCT00126659 2018-11-20
Sorafenib in Treating Patients Who Are Undergoing Surgery for Metastatic Kidney Cancer
National Cancer Institute (NCI)
Phase 2 Terminated
NCT00543335 2018-11-15
Sorafenib and Thoracic Radiation for Patients With Non-Small Cell Lung Cancer
M.D. Anderson Cancer Center
Phase 1 Terminated
NCT00734526 2018-11-09
Phase I Portion of Phase I/II Sorafenib With Radiation and Temozolomide in Newly Diagnosed Glioblastoma or Gliosarcoma
M.D. Anderson Cancer Center
Phase 1 Terminated
NCT02560012 2018-10-12
Personalized Targeted Inhibitors Treatment in Renal Cell Cancer
The University of Texas Health Science Center, Houston
Phase 2 Terminated
NCT03456401 2018-03-07
TOKIO
Fondazione IRCCS Istituto Nazionale dei Tumori, Milano
Phase 2 Terminated
NCT00722072 2018-02-26
Sorafenib and Fulvestrant in Treating Patients With Locally Advanced or Metastatic Breast Cancer That Did Not Respond to Aromatase Inhibitor Therapy
OHSU Knight Cancer Institute
Phase 2 Terminated
NCT00632541 2018-02-14
A Phase II Study of Bevacizumab + Sorafenib in Metastatic Breast Cancer
Hoosier Cancer Research Network
Phase 2 Terminated
NCT00126568 2018-01-19
Sorafenib in Treating Patients With Advanced Anaplastic Thyroid Cancer
National Cancer Institute (NCI)
Phase 2 Terminated
NCT00955721 2018-01-03
A Study of Combination of Gemcitabine, Oxaliplatin (GEMOX)-Sorafenib in Patients With Advanced Biliary Tract Cancer
University of Miami
Phase 1/2 Terminated
NCT02122003 2017-11-22
SOAP
Fondazione IRCCS Istituto Nazionale dei Tumori, Milano
Phase 2 Terminated
NCT01334710 2017-11-21
A Phase II Trial of OSI-906 and Sorafenib in Advanced Hepatocellular Cancer
Emory University
Phase 2 Terminated
NCT00801801 2017-05-17
Study of Low Dose Chemotherapy Plus Sorafenib as Initial Therapy for Patients With Advanced Non-Squamous Cell NSCLC
University of Alabama at Birmingham
Phase 2 Terminated
NCT01005875 2017-05-10
RAD 0901
University of Alabama at Birmingham
Phase NA Terminated
NCT01171482 2017-04-26
Comparison Study of Sorafenib and 5-fluorouracil/Mitomycin for Metastatic Hepatocellular Carcinoma
Seoul National University Hospital
Phase 2 Terminated
NCT01849588 2017-04-19
HCV-RNA Kinetics During Sorafenib for Hepatocellular Carcinoma (HCC)
Massachusetts General Hospital
Phase 4 Terminated
NCT02323906 2017-03-20
Safety and Efficacy Study of CC-122 Combined With Sorafenib for Primary Liver Cancer
Celgene
Phase 1 Terminated
NCT00576056 2017-02-15
Effectiveness and Safety Study of TACE Plus Oral Sorafenib for Unresectable HCC
University of Pittsburgh
Phase 2 Terminated
NCT00417248 2016-07-25
Cisplatin/Etoposide/Radiotherapy Followed by Consolidation Sorafenib for Inoperable Stage III Non-Small Cell Lung Cancer
Hoosier Cancer Research Network
Phase 1/2 Terminated
NCT00971126 2016-05-04
Study of Sorafenib With Combination of Thalidomide in Hepatocellular Carcinoma (HCC)
National Health Research Institutes, Taiwan
Phase 1/2 Terminated
NCT01480817 2016-04-29
Sorafenib VS TACE in HCC Patients With Portal Vein Invasion
Seoul National University Hospital
Phase 2 Terminated
NCT00510289 2016-04-19
Sorafenib in Myelodysplastic Syndrome
Duke University
Phase 2 Terminated
NCT00526799 2016-03-03
Sorafenib + Topotecan for Platinum-Resistant Recurrent Ovarian Cancer
Hoosier Cancer Research Network
Phase 1/2 Terminated
NCT00522301 2016-02-29
Sorafenib in Treating Patients With Ovarian Epithelial Cancer, Fallopian Tube Cancer, or Peritoneal Cancer in at Least the Second Remission
Memorial Sloan Kettering Cancer Center
Phase 2 Terminated